4//SEC Filing
Pitukcheewanont Pisit Duke 4
Accession 0001126234-24-000037
CIK 0001126234other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 5:10 PM ET
Size
8.5 KB
Accession
0001126234-24-000037
Insider Transaction Report
Form 4
LUMOS PHARMA, INC.(LUMO)
Pitukcheewanont Pisit Duke
Chief Medical Officer
Transactions
- Award
Common Stock
2024-04-01$2.84/sh+6,000$17,040→ 16,930 total - Award
Stock Option (Right to Buy)
2024-04-01+41,500→ 41,500 totalExercise: $2.84Exp: 2034-03-31→ Common Stock (41,500 underlying)
Footnotes (4)
- [F1]Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on April 1, 2025, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F2]Includes 3,938 RSUs granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on June 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F3]Includes 4,500 RSUs granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments with the next installment occurring on July 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F4]Grant to the Reporting Person of a stock option under the Plan. The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on May 1, 2024, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.
Documents
Issuer
LUMOS PHARMA, INC.
CIK 0001126234
Entity typeother
Related Parties
1- filerCIK 0002006724
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 5:10 PM ET
- Size
- 8.5 KB